6 research outputs found
Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity
Lassa mammarenavirus (LASV) is a rodent-borne arenavirus endemic to several West African countries. It is the causative agent of human Lassa fever, an acute viral hemorrhagic fever disease. To date, no therapeutics or vaccines against LASV have obtained regulatory approval. Polyclonal neutralizing antibodies derived from hyperimmunized animals may offer a useful strategy for prophylactic and therapeutic intervention to combat human LASV infections. The LASV envelope surface glycoprotein complex (GP) is the major target for neutralizing antibodies, and it is the main viral antigen used for the design of an LASV vaccine. Here, we assessed the immunogenic potential of mammalian cell-derived virus-like particles (VLPs) expressing GP from the prototypic LASV strain Josiah in a native-like conformation as the sole viral antigen. We demonstrate that an adjuvanted prime-boost immunization regimen with GP-derived VLPs elicited neutralizing antibody responses in rabbits, suggesting that effective antigenic epitopes of GP were displayed. Notably, these antibodies exhibited broad reactivity across five genetic lineages of LASV. VLP-based immunization strategies may represent a powerful approach for generating polyclonal sera containing cross-reactive neutralizing antibodies against LASV
Effects of Receptor Specificity and Conformational Stability of Influenza A Virus Hemagglutinin on Infection and Activation of Different Cell Types in Human PBMCs
Humans can be infected by zoonotic avian, pandemic and seasonal influenza A viruses
(IAVs), which differ by receptor specificity and conformational stability of their envelope
glycoprotein hemagglutinin (HA). It was shown that receptor specificity of the HA
determines the tropism of IAVs to human airway epithelial cells, the primary target of
IAVs in humans. Less is known about potential effects of the HA properties on viral
attachment, infection and activation of human immune cells. To address this question, we
studied the infection of total human peripheral blood mononuclear cells (PBMCs) and
subpopulations of human PBMCs with well characterized recombinant IAVs differing by
the HA and the neuraminidase (NA) but sharing all other viral proteins. Monocytes and all
subpopulations of lymphocytes were significantly less susceptible to infection by IAVs with
avian-like receptor specificity as compared to human-like IAVs, whereas plasmacytoid
dendritic cells (pDCs) and myeloid dendritic cells were equally susceptible to IAVs with
avian-like and human-like receptor specificity. This tropism correlated with the surface
expression of 2-3-linked sialic acids (avian-type receptors) and 2-6-linked sialic acids
(human-type receptors). Despite a reduced infectivity of avian-like IAVs for PBMCs, these
viruses were not less efficient than human-like IAVs in terms of cell activation as judged by
the induction of cellular mRNA of IFN-a, CCL5, RIG-I, and IL-6. Elevated levels of IFN-a
mRNA were accompanied by elevated IFN-a protein secretion in primary human pDC. We
found that high basal expression in monocytes of antiviral interferon-induced
transmembrane protein 3 (IFITM3) limited viral infection in these cells. siRNA-mediated
knockdown of IFITM3 in monocytes demonstrated that viral sensitivity to inhibition by
IFITM3 correlated with the conformational stability of the HA. Our study provides new
insights into the role of host- and strain-specific differences of HA in the interaction of IAVs
with human immune cells and advances current understanding of the mechanisms of viral
cell tropism, pathogenesis and markers of virulence
Development of sensitive methods for detection of porcine endogenous retrovirus-C (PERV-C) in the genome of pigs
Porcine endogenous retroviruses (PERV) represent a risk for xenotransplantation using pig cells, tissues or organs. PERV-A and PERV-B are present in the genome of all pigs and both infect human cells in vitro. PERV-C infects only pig cells and it is integrated in the genome of most, but not all pigs. Recombinants between PERV-A and PERV-C were described that infect human cells and replicate at high titres. To avoid such recombinations, PERV-C positive animals should not be used for breeding animals suited for xenotransplantation. In order to detect PERV-C positive pigs, different methods were developed such as specific PCRs using different primers, a highly sensitive nested PCR and a real-time PCR allowing measurement of proviral copy numbers. The real-time PCR was found to be useful to discriminate between contamination and actual provirus copies. The PCRs were optimized and their sensitivity was determined. Screening can be started with PCR1, if the result is negative, PCR2 to PCR5 or the nested PCR should be used, if the result is positive, the real-time PCR should be used to exclude contaminations. All methods were used to evaluate the prevalence of PERV-C and to identify PERV-C free animals. Due to the risk of contamination with cells from other animals testing should be performed with blood cells, not with ear biopsies
Bacterial vesicles block viral replication in macrophages via TLR4-TRIF-axis
Abstract Gram-negative bacteria naturally secrete nano-sized outer membrane vesicles (OMVs), which are important mediators of communication and pathogenesis. OMV uptake by host cells activates TLR signalling via transported PAMPs. As important resident immune cells, alveolar macrophages are located at the air-tissue interface where they comprise the first line of defence against inhaled microorganisms and particles. To date, little is known about the interplay between alveolar macrophages and OMVs from pathogenic bacteria. The immune response to OMVs and underlying mechanisms are still elusive. Here, we investigated the response of primary human macrophages to bacterial vesicles (Legionella pneumophila, Klebsiella pneumoniae, Escherichia coli, Salmonella enterica, Streptococcus pneumoniae) and observed comparable NF-κB activation across all tested vesicles. In contrast, we describe differential type I IFN signalling with prolonged STAT1 phosphorylation and strong Mx1 induction, blocking influenza A virus replication only for Klebsiella, E.coli and Salmonella OMVs. OMV-induced antiviral effects were less pronounced for endotoxin-free Clear coli OMVs and Polymyxin-treated OMVs. LPS stimulation could not mimic this antiviral status, while TRIF knockout abrogated it. Importantly, supernatant from OMV-treated macrophages induced an antiviral response in alveolar epithelial cells (AEC), suggesting OMV-induced intercellular communication. Finally, results were validated in an ex vivo infection model with primary human lung tissue. In conclusion, Klebsiella, E.coli and Salmonella OMVs induce antiviral immunity in macrophages via TLR4-TRIF-signaling to reduce viral replication in macrophages, AECs and lung tissue. These gram-negative bacteria induce antiviral immunity in the lung through OMVs, with a potential decisive and tremendous impact on bacterial and viral coinfection outcome. Video Abstrac